Wida Widiasih, Judiono Judiono, Witri Priawantriputri, Yohannes Willihelm Saleky

PENGEMBANGAN FORMULA ENTERAL GUDLEAI DIA PRO+ BERPROTEIN TINGGI BERBASIS KACANG KEDELAI, WHEY PROTEIN ISOLATE, DAN KACANG GUDE UNTUK PASIEN DIABETES MELITUS

Introduction

Pengembangan formula enteral gudleai dia pro+ berprotein tinggi berbasis kacang kedelai, whey protein isolate, dan kacang gude untuk pasien diabetes melitus. Kembangkan formula enteral tinggi protein Gudleai Dia Pro+ dari kedelai, whey, & kacang gude untuk pasien diabetes melitus tipe 2. Mengatasi malnutrisi dengan nutrisi lengkap & ekonomis.

Abstract

Malnutrition is a common condition among patients with type 2 diabetes mellitus (T2DM), primarily caused by metabolic dysregulation, unbalanced dietary patterns, diabetes-related complications, and recurrent infections. Adequate intake of high-quality protein plays a crucial role in preventing malnutrition in this population. This study aimed to develop and evaluate a high-protein enteral formula based on soybeans, whey protein isolate, and pigeon pea as a potential nutritional intervention for T2DM patients without renal impairment. The evaluation included assessments of organoleptic properties, macronutrient composition, dietary fiber content, antioxidant activity, energy density, flow rate, shelf life, and economic feasibility. An experimental design was employed, involving 15 trained panelists for sensory analysis. The Mann–Whitney test revealed significant differences between formulas F1 and F3 in terms of taste and aroma (p < 0.05), with no significant differences in color, consistency, or overall acceptance (p > 0.05). Formula F2 demonstrated superior sensory attributes compared to F3 in all evaluated aspects (p < 0.05). Proximate and antioxidant analyses of the optimized formula (F2 - Gudelai Dia Pro+) showed an energy content of 273 kcal, protein 16.22 g, fat 9.14 g, carbohydrates 31.47 g, dietary fiber 2.51 g, and antioxidant activity of 150.12 µg/ml. The formula exhibited an energy density of 1.31 kcal/cc and a flow rate of 1.06 ml/sec. Shelf-life testing indicated a decline in quality after 12 hours at room temperature. Cost analysis revealed that Gudelai Dia Pro+ had a production cost of IDR 11,165 per serving, making it more cost-effective than commercial enteral formulas by a margin of IDR 1,835  

Review

This study presents a timely and relevant investigation into the development of a high-protein enteral formula, "Gudelai Dia Pro+", specifically tailored for patients with type 2 diabetes mellitus (T2DM) prone to malnutrition. The innovative use of a blend of soybeans, whey protein isolate, and pigeon pea (kacang gude) forms a unique nutritional matrix, promising a comprehensive approach to address the specific dietary needs of this vulnerable population. The abstract clearly articulates the clinical rationale and the systematic evaluation methodology, which includes crucial parameters such as organoleptic properties, macronutrient composition, antioxidant activity, and economic feasibility, highlighting a well-structured initial assessment of its potential. A significant strength of this research lies in its comprehensive evaluation strategy. The experimental design, employing trained panelists and appropriate statistical analysis for sensory attributes, effectively identified an optimized formula (F2) with superior acceptance. The detailed proximate analysis of "Gudelai Dia Pro+" reveals an impressive nutritional profile, featuring high protein content (16.22g), a commendable energy density (1.31 kcal/cc), notable antioxidant activity (150.12 µg/ml), and beneficial dietary fiber (2.51g). Crucially, the practical considerations, including a suitable flow rate and a demonstrable cost-effectiveness compared to commercial alternatives, underscore the formula's potential for real-world applicability and accessibility. While the study provides a strong foundation for this novel enteral formula, certain aspects warrant further consideration and investigation. The reported shelf life of only 12 hours at room temperature presents a notable practical limitation for broader implementation, especially for home-based nutritional support, suggesting a need for further research into stability enhancement. Moreover, despite the comprehensive *in vitro* characterization, the ultimate validation of efficacy and safety for T2DM patients would necessitate rigorous *in vivo* clinical trials to assess its impact on glycemic control, nutritional markers, and overall patient outcomes. Nevertheless, this research represents a valuable contribution to medical nutrition, offering a promising, cost-effective, and nutritionally robust enteral option for T2DM patients without renal impairment, meriting further clinical development.

Full Text

Comments

You need to be logged in to post a comment.